The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Background: Psoriasis, a common inflammatory disease, is associated with atherosclerotic
vascular diseases, including stroke, myocardial infarction, and impaired microcirculations,
among which circulating microparticles play an important role. In severe psoriasis, there are
increased endothelial- and platelet- microparticles that are reduced by TNF-α blockers in
parallel with clinical improvement. However, whether Stelara(ustekinumab) treatment would
decrease the level of microparticles remains unknown.
Objective: The investigators will evaluate the level of microparticles among normal control,
severe psoriasis before and 4 months after ustekinumab treatment.